EC approves Pfizer’s Litfulo for adolescents and adults with alopecia
Betsy Goodfellow | September 19, 2023 | News story | Medical Communications | Dermatology, EC, Litfulo, alopecia
Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent patients over the age of 12 with sever alopecia areata.
The once-daily oral capsule is the first drug to be approved by the EC for the treatment of patients as young as 12 with severe alopecia areata. The drug is also the first and only treatment to selectively inhibit Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases.
This approval follows a recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2023. The US Food and Drug Administration (FDA) and Japanese Ministry of Health, Labour and Welfare (MHLW) in June 2023.
Angela Hwang, chief commercial officer and president of the Global Biopharmaceuticals Business at Pfizer, commented: “Today’s approval of Litfulo in Europe is an important milestone for patients as young as 12 years of age with substantial hair loss from alopecia areata, as they now have an opportunity to achieve significant hair regrowth. Previously, there were no treatment options approved by the EC for adolescents with severe alopecia areata, and Pfizer is proud to be bringing forward this new innovative medicine for patients living with the challenges brought by this autoimmune disease.”
Betsy Goodfellow
Related Content
NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
